AMX0035 sodium phenylbutyrate-taurursodiol
Selected indexed studies
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (N Engl J Med, 2020) [PMID:32877582]
- Sodium Phenylbutyrate. (, 2006) [PMID:36701505]
- Sodium Phenylbutyrate and Taurursodiol. (Am J Health Syst Pharm, 2023) [PMID:36645072]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (2020) pubmed
- Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial. (2024) pubmed
- Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. (2024) pubmed
- Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls. (2023) pubmed
- Sodium Phenylbutyrate. (2006) pubmed
- Sodium Phenylbutyrate and Taurursodiol. (2023) pubmed
- Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease. (2024) pubmed
- An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. (2023) pubmed
- Real-World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States. (2025) pubmed
- Addendum: Relyvrio withdrawn. (2024) pubmed